AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...

Though sales in China were down, the British pharmaceutical company beat industry expectations following an uptick in cancer ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its ...

AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025. The Cambridge-based pharmaceuticals firm ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...